Intercept Pharmaceuticals CEO Mark Pruzanski on first NASH drug – Business Insider


NASH is a liver disease that affects millions of Americans. Researchers expect it to become the leading cause of liver transplants in the US within the next few years.The drug industry has suffered multiple failures in the hunt for NASH treatments over the years.But now Intercept Pharmaceuticals is preparing to launch the first treatment for NASH.If approved, Intercept plans to focus on about 500,000 Americans. Wall Street analysts expect the drug to eventually generate $3.5 billion in yearly sales, according to the market-research firm EvaluatePharma.Intercept CEO Mark Pruzanski talked to Business Insider about the company’s commercial strategy and plans to establish the treatment market for the disease.Visit Business Insider’s homepage for more stories. In the early 2000s, Mark Pruzanski was running Intercept Pharmaceuticals from the living room of his New
Read More